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Abstract
Purpose Patient-reported outcome measures (PROMs)
are designed to assess patients’ perceived health states or
health-related quality of life. However, PROMs are sus-
ceptible to missing data, which can affect the validity of
conclusions from randomised controlled trials (RCTs).
This review aims to assess current practice in the handling,
analysis and reporting of missing PROMs outcome data in
RCTs compared to contemporary methodology and
guidance.
Methods This structured review of the literature includes
RCTs with a minimum of 50 participants per arm. Studies
using the EQ-5D-3L, EORTC QLQ-C30, SF-12 and SF-36
were included if published in 2013; those using the less
commonly implemented HUI, OHS, OKS and PDQ were
included if published between 2009 and 2013.
Results The review included 237 records (4–76 per rel-
evant PROM). Complete case analysis and single imputa-
tion were commonly used in 33 and 15 % of publications,
respectively. Multiple imputation was reported for 9 % of
the PROMs reviewed. The majority of publications (93 %)
failed to describe the assumed missing data mechanism,
while low numbers of papers reported methods to minimise
missing data (23 %), performed sensitivity analyses (22 %)
or discussed the potential influence of missing data on
results (16 %).
Conclusions Considerable discrepancy exists between
approved methodology and current practice in handling,
analysis and reporting of missing PROMs outcome data in
RCTs. Greater awareness is needed for the potential biases
introduced by inappropriate handling of missing data, as
well as the importance of sensitivity analysis and clear
reporting to enable appropriate assessments of treatment
effects and conclusions from RCTs.
Keywords Missing data  Randomised controlled trials
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Background
Over the last 20 years, clinicians and policy makers have
increasingly become aware of the importance of incorpo-
rating the patient perspective to inform patient care and
policy decisions [1, 2]. As a consequence, a large number
of instruments have been developed to collect information
on patients’ perceived health states or their perceived
health-related quality of life (HRQOL) [3, 4]. Often
referred to as patient-reported outcomes (PROs) or patient-
reported outcome measures (PROMs), these measures
include ‘any report coming directly from patients, without
interpretation by physicians or others, about how they (the
patients) function or feel in relation to a health condition
and its therapy’ [5].
PROMs are an important addition to traditional mea-
sures of outcome, such as clinical assessment, morbidity
and mortality, which may not fully capture the patient
experience of a specific treatment or disease burden.
Therefore, PROs are increasingly used as primary and
secondary endpoints in randomised controlled trials
(RCTs) [1, 2].
However, RCTs utilising PROMs rely on their partici-
pants to be able and willing to complete the relevant out-
come measures throughout their follow-up period. It is
therefore often impossible to obtain complete follow-up
PROMs data for all randomised participants [6], and the
subsequently arising missing data within those RCTs can
question their ability to provide reliable patient-reported
effectiveness and cost-effectiveness estimates of potential
interventions [7].
Missing data background
Missing data are defined as data that were intended to be
collected within the remit of a study, and considered rel-
evant to the statistical analysis and interpretation of the
results, but which are unavailable at the time of the analysis
[8].
Statistical methodology commonly refers to three
missing data mechanisms, which were first defined by
Little and Rubin in 1987 [9]. In simple terms, they describe
if the probability of an observation being missing is (1)
unrelated to any of the observed or unobserved data
(missing completely at random—MCAR), (2) related to the
observed data (missing at random—MAR) and (3) related
to the unobserved outcome data (missing not at random—
MNAR).
Based on the available data, it is impossible to defini-
tively assign one of these missing data mechanisms to the
data. Yet, if the assumed mechanism is not correct, the
results from the statistical analysis may be biased [10],
making it imperative to perform adequate sensitivity
analyses which vary the assumptions made in the primary
analysis about the underlying missing data mechanism
[11].
Overview of statistical approaches to missing data
Various approaches have been developed for handling
missing data in statistical analyses, which can be divided
into the following categories [12, 13]: (1) available/com-
plete case analysis excludes all observations with missing
data in any of the relevant variables; (2) single imputation
techniques replace the missing value with a value based on
either previously observed data for that individual (last
observation carried forward—LOCF), the mean of avail-
able data (mean imputation) or informed by a range of
other variables (regression imputation); (3) multiple
imputation techniques are drawn on other observed data to
impute a range of possible values; separate analysis models
are run for each of these imputed values and pooled to take
into account the uncertainty around the missing data; and
(4) model-based approaches include maximum likelihood
methods and mixed-effects models for longitudinal data,
which do not require the imputation of missing values.
Whether RCT results are biased due to the occurrence of
missing data, and how much bias is introduced as a result
depends on a multitude of factors, mainly the extent of
missing data within the study and within each trial arm, the
appropriateness of the assumptions made about the
underlying missing data mechanism and the subsequent
handling of the missing data in the analysis [6]. Analyses
will be unbiased under MCAR, and also under MAR if the
analysis adjusts for all variables the probability of missing
data is related to, although the power of the study is
decreased due to the reduced sample size.
RCTs form the basis for many important healthcare
decisions [7], such as the approval of new or modified
drugs, devices or interventions, and changes to clinical
guidelines or practice [14]. If these decisions are informed
by biased data, due to the inappropriate handling and
reporting of missing data within the underlying RCTs, this
could lead to substandard or even harmful treatments being
recommended and adversely affect patient welfare.
Previous reviews [15–22] have identified substandard
handling and reporting of missing primary outcome data in
RCTs and epidemiological studies, the use of inappropriate
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methods to account for missing data and the lack of sen-
sitivity analyses to assess the robustness of study results, all
highlighting the need for clearer reporting of missing data
within studies.
The literature on how missing data should be handled
and reported is manifold and covers methods of imputation
[11, 23–26], analysis methods [9, 11, 12] and reporting
standards [14, 27–29]. However, specific advice on han-
dling missing PROMs data is less common. A systematic
review and Delphi consensus by Li et al. [10] consolidated
the literature into a set of ten standards that should be
applied for the prevention and handling of missing data in
research utilising PROMs.
Aims of this review
This work aims to:
• Create an overview of the current practice of handling,
analysis and reporting of missing PROMs outcome data
(including both primary and secondary endpoints) in
journal publications of RCTs, thus updating previous
reviews.
• Compare the currently used methods to handle, analyse
and report missing PROMs outcome data in RCTs
against recommended best practice.
Methods
Basis for the comparison
Assessment of study design, analysis and reporting in the
review was based on seven of the ten criteria recommended
by Li et al. [10], as listed in Table 1. The remaining three
criteria related to study design (clear definition of research
question and primary endpoints) and study conduct (con-
tinued collection of key outcomes and monitoring of
missing data) were outside the remit of this review as they
relate to the protocol and internal trial conduct and may
therefore not be directly assessable based on the publica-
tions reporting on trial results.
When designing this review, it was felt important to
include questionnaires from four key PROMs areas,
namely preference-based measures (which can be used in
health economics evaluations), generic health profiles,
disease-targeted questionnaires and anatomical site-specific
questionnaires. Two PROMs within each category were
selected, using the criteria that they were validated and had
been widely adopted and that they aligned with the authors’
research interests and experience:
• Utility measures: EuroQol EQ-5D-3L Questionnaire
[30, 31] and Health Utility Index (HUI) [32], whereby
articles utilising any of the available HUI versions
(including HUI-1, HUI-2 and HUI-3) were eligible for
inclusion.
• Generic health profiles: Short-Form 12 (SF-12) [33]
and Short-Form 36 (SF-36) [34] health surveys.
• Site-specific questionnaires: Oxford Hip Score (OHS)
[35, 36] and Oxford Knee Score (OKS) [36, 37].
• Disease-targeted questionnaires: European Organiza-
tion for Research and Treatment of Cancer Quality of
Life Questionnaire-Core 30 (EORTC QLQ-C30) [38]
and Parkinson Disease Questionnaire (a combination of
the PDQ-8 and PDQ-39 was considered) [39, 40].
Database search
Multiple databases [EMBASE, PubMed, Web of Science,
NHS Economic Evaluation Database (NHS EED, for the
two preference-based measures only)] were searched to
identify recent publications of RCT results utilising at least
one relevant questionnaire as either a primary or secondary
endpoint. To minimise the risk of missing potentially rel-
evant articles, very general search terms were used to
Table 1 Reporting standards defined by Li et al. assessed in this review
Proposed standards Aspects assessed within the literature review
Standards on study
design
Steps have been taken and reported to conduct the study in a way to minimise missing data
Standards on analysis Single imputation methods are avoided
The analytical and/or imputation methods used are able to account for the uncertainty associated with missing data
Appropriate sensitivity analysis examines the robustness of results with regard to the assumptions about the missing
data mechanism
Standards on reporting All randomised participants are accounted for in the results
Appropriate reporting of the extent of missing data and methods to handle it
Discussion of the potential influence of missing data on the study results
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identify publications, using the words (random*) and
(clinical* or trial or RCT) and terms describing the relevant
questionnaire names or abbreviations. Figure 1 depicts the
number of articles identified in the initial searches, the
screening process and the identification of eligible papers.
Eligibility of articles
Publications were considered eligible if the results from
definitive RCTs utilising relevant PROMs were reported in
English and at least 50 patients were randomised to each of
the relevant trial arms. This cut-off was chosen to include
studies of sufficient size to have permitted the use of
potentially complex methods of handling missing data and
quantitative assessments between treatment arms; the gen-
eralisability from smaller studies is likely to be unreliable.
Due to large numbers of articles identified, searches were
restricted to 2013 for the EQ-5D-3L, QLQ-C30 and SF-12,
SF-36, while data extraction was extended to include years
2009–2013 for the HUI, OHS, OKS and PDQ.
Publications reporting cost-effectiveness analyses
alongside clinical trials and using EQ-5D-3L or HUI data
were included, but publications based primarily on
extrapolations beyond the trial follow-up or on decision
analytical models were excluded, as were publications
reporting on aggregate data from two or more studies.
Crossover studies were excluded from this review as the
impact on each missing observation is greater compared to
a parallel group design, and RCTs analysed within a fac-
torial design framework were excluded as the analytical
methods employed tend to differ from those for parallel
group designs and may make the imputation of missing
values more challenging. Most of the identified trials
allocated participants to two groups. Trials with more than
two arms were included in the review; however, for sum-
maries relying on the direct comparison between two arms
as well as the sample size, only two arms of the multi-arm
trials were considered (i.e. the arm using the combination
of most drugs or most frequent intervention appointments
and the control arm).
Data extraction
Information was extracted from each eligible research
article on study characteristics and adherence with report-
ing items recommended by Li et al. [10]. A full list of items
extracted can be seen in the electronic supplementary
material.
Data extraction was performed by one investigator (IR),
with queries resolved by consultation with the other
authors. Abstracts and methods sections were read in full,
while a keyword search was used to identify relevant
information in other sections of the articles.
Findings were summarised descriptively overall and by
PROM using frequency and percentages for categorical
data and medians, interquartile range and range for con-
tinuous data.
Results
The number of identified eligible studies varied widely,
from over 70 studies using the EQ-5D-3L index and SF-36
identified in 2013 alone, to less than ten studies utilising
the OKS and OHS identified between 2009 and 2013, as
shown in Fig. 1. Where an eligible publication reports on
several of the pre-specified outcome measures, this study is
included in the summaries for all relevant PROMs and
more than once in the overall summaries (i.e. this review
includes 237 records relating to 209 articles).
Table 2 shows that the sample size of the RCTs included
into this review also varies, from a total sample size of 100
(the cut-off for eligibility to be included into the review,
i.e. at least 50 participants in both of the two relevant trial
arms), up to over 18,000 participants randomised across 43
countries.
The percentage of studies using the relevant PROMs as
a primary outcome measure was highest for those utilising
the HUI with almost 70 % and lowest for the OHS, QLQ-
C30, SF-12 and SF-36 with approximately 25 %. RCTs
using the QLQ-C30 often favoured primary endpoints
focussing on survival or progression-free survival, while
RCTs utilising the SF-36 often used primary endpoints that
were more disease targeted. Alternative site-specific
instruments may have been used as primary endpoints in
RCTs that utilised the OHS or OKS. Outcomes were
measured repeatedly during the follow-up period in the
vast majority of studies (82 % on average). Studies with a
single follow-up time point often had a very short duration
of follow-up.
Full details of the study characteristics are given in
Table 2.
Missing data within the identified publications
On average, only 40 % of studies clearly stated the number
of participants for whom relevant PROMs data were
available at the main follow-up point; overall, approxi-
mately 37 % of all studies reported this information by
randomisation allocation.
The median percentage of available PROMs data at the
primary assessment time point, where reported, was 75 %,
although data availability ranged from\30 to 99 %. Evi-
dence of differential loss of follow-up between the trial
arms was observed, with up to 15 % more data being
missing in either trial arm, as reported in Table 3.
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EMBASE 
2009-2013*, or  
In 2013 alone** 
EQ-5D-3L**:  115 
HUI*:  1592 
OHS*:  40 
OKS*:  41 





2009-2013*, or  
in 2013 alone** 
EQ-5D-3L**:  310 
HUI*:  71 
OHS*:  105 
OKS*:  41 




Web of Science 
2009-2013*, or  
in 2013 alone** 
EQ-5D-3L**:  137 
HUI*:  47 
OHS*:  35 
OKS*:  31 





2009-2013*, or  
in 2013 alone**
EQ-5D-3L**:  26 
HUI*:  50 
OHS*:  n/a 
OKS*:  n/a 




the review of other 
PROMs 
EQ-5D-3L**:  4 
HUI*:  4 
OHS*:  0 
OKS*:  0 




removal of  
duplicates: 
EQ-5D-3L:  450 
HUI:  1685 
OHS:  122 
OKS:  78 
PDQ:  173 
QLQ-C30: 122 
SF-12:  193 

















Conference abstracts  1 14 1 0 0 0 1 1 
Methodology/ guidance  11 40 2 3 0 1 5 8 
Pilot/ feasibility study  16 8 2 2 7 3 3 22 
Reviews/ meta analyses  31 162 4 10 15 14 17 94 
7015321015315131slocotorP
Acronym not related to relevant 
PROMs 
0 1 74 7 54 0 0 0 
Papers misclassiﬁed (HUI part of name 
in author list, acknowledgements or 
references) 
0 707 0 0 0 0 0 0 
1122712445rehtO
11594177431847015951833LATOT
full text copies  
retrieved to assess 
eligibility 
EQ-5D-3L:  112 
HUI:  90 
OHS:  15 
OKS:  30 
PDQ:  39 
QLQ-C30: 45 
SF-12:  44 
SF-36:  200 




HUI:  13 
OHS:  4 
OKS:  9 
PDQ:  17 
QLQ-C30: 21 
SF-12:  25 
SF-36:  76 

















Cross-over/ factorial design  2 6 0 1 2 0 1 3 
PROM not used as endpoint 9 44 2 2 1 5 3 21 
HTA monograph 6 0 0 0 0 0 1 0 
Focus not on diﬀerence be-
tween treatment arms 



















Fig. 1 PRISMA flow diagramm detailing the identification process of studies for inclusion in the review
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Reporting and handling of missing data
within the identified publications
Full details on the approaches to handling missing data are
given in Table 4. With the exception of RCTs using the
OHS and SF-12, only one-quarter or less of publications
mentioned the use of strategies employed to minimise the
occurrence of missing data within the study. Reported
strategies to increase response rates included the provision
of prepaid envelopes to increase returns of postal ques-
tionnaires, alternative assessments where clinic visit could
not be attended (e.g. postal questionnaires, telephone
interviews, home visits), as well as reminders where fol-
low-up data were not received (i.e. emails, phone calls,
letters). Other approaches involved payments or rewards
for questionnaire completion, reiterations to participants
and staff that data collection was encouraged even after
withdrawal from the allocated intervention and the
Table 2 Overview of the characteristics of the identified RCTs by PROM category
Questionnaires EQ-5D-3L
index
HUI OHS OKS PDQ QLQ-
C30
SF-12 SF-36 Overall
Number of studies 72 13 4 9 17 21 25 76 237
Years included 2013 2009–2013 2009–2013 2009–2013 2009–2013 2013 2013 2013 2009–2013
Studies using PROM
as a primary outcome
(%)
38.9 69.2 25.0 44.4 41.2 23.8 24.0 26.3 33.8
Size of studiesa
Median 329 255 155 165 294 309 241 202 251
IQR 190–600 139,622 n/a 120–200 184–359 178–420 195–392 138–304 159–416





87.5 92.3 50.0 88.9 76.47 81.0 84.0 77.6 82.3
Length of follow-up to primary assessment time point (in months)
Median 12 12 18 12 6 12 9 15 12
IQR 6–17 10.5–22 7.5–36 12–24 4–10.5 6–12 6–15 4–12 6–15
Range 1–60 6–36 3–48 3–60 3–36 0.25–78 1.5–24 0.75–60 0.25–78
a The size of the studies described here refers to the number of participants randomised to the two relevant treatment arms considered in this
review
Table 3 Overview of the amount of missing data within the identified RCTs by PROM category
Questionnaires EQ-5D-
3L index
HUI OHS OKS PDQ QLQ-
C30
SF-12 SF-36 Overall
Number of studies 72 13 4 9 17 21 25 76 237
% of data available at primary



















Median (%) 74.8 76.2 63.3 83.7 83.2 50.7 68.6 84.2 75.0
IQR (%) 59.7–85.7 47.6–74.6 61.9–80.8 69.7–94.7 57.1–86.2
Range (%) 34.1–91.6 50.7–86.2 55.9–70.7 62.4–98.8 51.8–94.5 35.1–85.4 37.1–90.5 26.0–99.2 26.0–99.2
% difference in follow-up data



















Median 0.3 3.7 -2.0 -2.2 4.91 6.6 5.1 -0.5 0.3


























a The first lines of the summaries specify the number (and percentage) of studies for which this information is available
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exclusion of potential participants that were unlikely or
unable to comply with follow-up visits, including those
with terminal diagnosis or hospice care.
The vast majority of publications (more than 90 %
overall) did not state the assumed missing data mechanism,
and the relationship of missing data to baseline character-
istics was rarely investigated (20 % of publications over-
all). In many cases, the analysis population was not clearly
described (27 % of publications overall).
Many authors (17–62 %) did not clearly describe the
primary method of handling missing data in the analysis.
Complete case analysis was the most widely used analytic
approach found in this set of publications (6–50 %). Mul-
tiple imputation and repeated measures models were less
frequently used, in up to 16 and 25 % of publications,
respectively.
A small number of authors justified their primary
method of dealing with missing data (between 0 and 25 %
across the PROMs examined), reported sensitivity analysis
to assess the robustness of their results with regard to the
assumed missing data mechanism (0–32 %) or commented
on the potential influence of missing data on the study
results (0–25 %). Even when sensitivity analyses were
undertaken, these seldom included varying the assumptions
made about the underlying missing data mechanism.
Examples of this included cases where the primary analy-
ses utilised a complete case analysis and the associated
sensitivity analyses consisted of single/multiple imputation
or repeated measures models, or vice versa, or the addition
of all variables that had been identified to be predictive of
missing data into the analysis model.
Very few examples utilising the reasons for missing data
in the imputation of missing values were identified,
including the substitution of missing values in the EQ-5D-
3L index for those who had died with zeros (i.e. the EQ-
5D-3L health state equal to being dead) [41], using QLQ-
Table 4 Overview of the approaches to handling missing data within the identified RCTs by PROM category
Questionnaires EQ-5D-3L
index
HUI OHS OKS PDQ QLQ-
C30
SF-12 SF-36 Overall
Number of studies 72 13 4 9 17 21 25 76 237
Methods to limit missing data described (%) 25.0 15.4 50.0 22.2 11.8 14.3 36.0 21.1 22.8
Differential missingness assessed (%)a 25.0 15.4 0 11.1 11.8 14.3 28.0 18.4 19.8
Assumed missing data mechanism
Not described (%) 91.7 100 100 100 82.4 100 88.0 96.0 93.7
Missing at random (%) 6.9 – – – 17.6 – 12.0 4.0 6.3
Missing completely at random (%) 1.4 – – – – – – – 0.42
Missing data mentioned in methods/analysis section (%) 62.5 53.9 25.0 11.1 75.0 42.9 52.0 52.6 54.2
Analysis population
Intention to treat (%) 27.8 7.7 – 11.1 29.4 9.5 24.0 19.7 21.1
Modified intention to treat (%) 54.2 46.2 50.0 66.7 47.1 59.1 48.0 46.1 50.6
Per protocol (%) 1.4 – – – 5.9 – – 1.3 1.3
Unclear (%) 16.7 46.2 50.0 22.2 17.7 33.3 28.0 32.9 27.0
Primary method of handling with missing data
Complete cases (%) 38.9 30.8 50.0 22.2 5.9 14.3 32.0 39.5 32.9
Last observation carried forward (%) 11.1 7.7 – 11.1 41.2 9.5 4.0 10.5 11.8
Mean imputation (%) 5.6 – – – – – 4.0 2.7 3.0
Regression imputation (%) – – – – – – 4.0 – 0.4
Direct likelihood analysis (%) – – – – 5.9 – – – 0.4
Repeated measures model (%) 8.3 15.4 – 11.1 17.7 14.3 20.0 25.0 16.9
Multiple imputation (%) 15.3 15.4 – – – – 16.0 5.3 8.9
Unclear (%) 20.8 30.8 50.0 55.6 29.4 61.9 20.0 17.1 26.2
Justification provided for primary method of dealing with
missing data (%)
13.9 15.4 25.0 0 11.8 0 8.0 5.3 8.9
Sensitivity analysis was performed (%) 25.0 23.1 25.0 0 17.7 19.1 32.0 19.7 21.9
Potential influence of missing data on results mentioned in
discussion (%)
18.1 15.4 25.0 0 17.7 14.3 16.0 14.5 15.6
a The studies considered differences between those with complete and missing data in terms of participant (baseline) characteristics
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C30 averages for missing data due to administration errors
and lower scores for missing data due to refusal, illness,
death [42] and imputing missing data with the best and
worst observed scores [43] in order to assess the effect of a
MNAR assumption on their results. However, none of
these single imputation techniques took into account the
uncertainty around the imputed values.
Subset of articles using PROMs as a primary
endpoint
The above summaries considered publications utilising the
relevant PROMs as either a primary or secondary outcome.
When focussing on the subset of articles utilising the rel-
evant PROMs as a primary outcome measure only (80
PROMs, approximately one-third of all PROMs and
24–69 % of each relevant PROMs category), the standard
of reporting improved marginally. More specifically, for
some of the PROMs, an increase in the proportion of
studies mentioning methods for reducing the amount of
missing data within the studies could be observed, along
with an increase in the clarification of how much PROMs
data are available at the primary follow-up point and an
overall decrease of the amount of missing data at follow-
up. Overall, the proportion of articles that performed and
reported sensitivity analyses increased. On the other hand,
the proportion of studies using LOCF in their primary
analysis and not clearly stating their analysis population
also increased when only considering studies using relevant
PROMs as a primary outcome measure.
Discussion
This research shows that despite the wide availability of
published guidance on this topic, the handling, analysis and
reporting of missing PROM data in RCTs often failed to
follow the current recommended best practice. Many
authors did not comply with basic advice about the
reporting of missing outcome data in RCTs, as also found
in the previous reviews [15–22]. A lack of adequate
reporting on attrition, i.e. missing data due to loss to fol-
low-up in RCTs, was also discussed by Hopewell et al.
[44].
Particularly noticeable in the present survey was the
failure of many publications to describe clearly the extent
of missing PROMs outcome data. CONSORT diagrams
detailing the number of participants who died or were lost
to follow-up did not capture the amount of missing data
that occur due to questionnaire non-compliance or partly/
incorrectly completed questionnaires. This, together with
the lack of clarity on how missing data were handled in the
analysis, made it impossible for the reader to assess the risk
of bias arising from missing data in the reported results.
Where missing data occurred partly by design (i.e. only a
subgroup of participants was included into the PROMs
research, because participants with disease progression or
other patient characteristics are excluded, or because of a
high mortality rate in the study making the collection of
PROMs impossible for a large proportion of participants
[45]), authors ought to ensure that results and interpreta-
tions are provided within this context, instead of extrapo-
lating the conclusions inappropriately to the entire trial
population.
In addition, the continued use of imputation methods
that are known to introduce bias, such as LOCF [46, 47],
further puts into question the validity of some study results.
Furthermore, there is limited evidence of repeatedly
measured outcome data being taken into account for the
PROMs analysis when it may be very informative for the
imputation process.
The importance of sensitivity analysis to assess the
robustness of the study results with regard to the
untestable assumptions about the underlying missing data
mechanism has been highlighted repeatedly in the literature
[6, 7, 10, 48, 49]. The results presented here showed that
sensitivity analysis has only been described in a low per-
centage of articles. Even where sensitivity analysis has
been performed, the sensitivity of the assumptions made
about missing data in the primary analysis was often not
investigated, as suggested in the current literature [10], thus
making it impossible for the reader to assess the robustness
of results in relation to variations about the assumed
missing data mechanism. As there was evidence of dif-
ferent rates of loss to follow-up by trial arm in many trials,
there may be a need to consider MNAR mechanisms.
The potential influence of missing data on study results
was rarely discussed, thus leaving the study results open to
misinterpretation.
Finally, the number of publications reporting the meth-
ods to minimise the occurrence of missing data used in
planning and conducting the study was found to be low.
This is disappointing since no statistical analysis, however
advanced, can replace information obtained by more
complete follow-up. Therefore, researchers should be
aware that in dealing with missing data ‘the single best
approach is to prospectively prevent missing data occur-
rence’ [10].
Strength and limitations of the study
This review adds to the current literature by focusing on
recent publications and offering additional, very important
aspects to the assessment of the handling and reporting of
missing data in RCTs. Novel aspects included an
1620 Qual Life Res (2016) 25:1613–1623
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investigation into the reporting of steps taken to minimise
the occurrence of missing data and whether differential
missing data rates by trial arm were considered in the
analysis and reporting of the trial, as well as a justification
of the chosen method for dealing with missing data and the
use of sensitivity analysis.
By attempting to create a broad picture of current
practice through including publications from a wide range
of journals, rather than focussing on specific journals only,
as in some of the previous reviews [15, 16, 20, 21], it was
necessary to limit the review to a certain number of out-
come measures. Though it is hoped that the reporting
practice observed in the subset of representative outcome
measures is generalisable to other PROMs, it is possible
that there may be PROMs for which the handling, analysis
and reporting of missing data is different from the standard
of reporting as presented here.
Only very few eligible studies were identified for some
PROMs (especially, the OHS and OKS, with four and nine
studies, respectively, included in the review). Reasons for
this included the fact that these site-specific measurements
are just two of many other PROMs designed to be used for
similar assessments [50–52]. Additionally, the pool of
studies utilising these PROMs will naturally be smaller
than for PROMs designed to measure a broader range of
disease areas. Arguably, the low numbers of articles
identified produced a less generalisable picture of the
analysis and reporting practice of RCTs utilising these
PROMs.
Generalisability is also limited to larger RCTs (due to
the inclusion criteria of C50 participants per arm) and may
not apply to the large amount of RCTs conducted that do
not meet this sample size, including many single-centre
studies, which are likely to differ from larger multicentre
studies in terms of data collection, attrition and analysis
methods.
The NHS EED database was included into the search
strategy for the EQ-5D-3L and HUI, as it was considered to
be very reliable in identifying the utility questionnaires.
However, NHS EED relies on articles having been
reviewed by the York team, and therefore, the entries for
2013 may not have been as up to date at the time of the
review as the entries for earlier years would have been.
The follow-up periods in this review ranged from a few
months to several years, as shown in Table 2. This may
have been one of the reasons for the large variety in the
observed extent of loss to follow-up.
The focus of this review was on the handling and
reporting of missing PROMs outcome data, and missing
data at baseline have not been within the remit of this
research. Although less prevalent in RCTs than in epi-
demiological studies, it is recognised that missing baseline
data also have the potential of biasing a study and certainly
reduce the power in a complete case analysis. Therefore,
authors should carefully consider how to report missing
baseline data in their analyses, and multiple imputation
approaches in line with the current literature may be
advisable.
How authors reported potentially conflicting results
from the primary and sensitivity analyses was not assessed
because the review did not include sufficient numbers of
appropriate sensitivity analyses to extract any meaningful
information.
This work has not been able to relate the quality of
reporting to word limits imposed by journals which may
contribute to important details about missing data being
omitted in favour of other relevant information. However,
much of the information on data availability and analysis
populations can be depicted in the tables and well-designed
CONSORT flow charts. Details of assumptions about
missing data mechanisms, analysis strategy and sensitivity
analysis can be reported briefly with one or two sentences
in the main text.
Conclusions
This review provides evidence that a considerate discrep-
ancy exists between the guidance and methodology on the
handling, analysis and reporting of studies with missing
PROMs outcome data compared to current practice in the
publications of RCTs. The substandard level of reporting
makes it challenging for clinicians, healthcare providers
and policy makers to know how reliable the results from
RCTs are, and may even lead to healthcare decisions being
based on sub-optimal information.
Greater awareness needs to be created about the
potential bias introduced by the inappropriate handling of
missing data and the importance of sensitivity analysis.
Subsequently, the handling of missing data, especially in
PROMs, as well as its detailed and consistent reporting
needs to be improved to adhere with current methodology
and hence enable an appropriate assessment of any treat-
ment effects and the associated conclusions in the publi-
cations of RCTs. Ensuring that researchers trained in
statistics are among the authors and involved in the study
design is thought to contribute to improving standards.
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